A New Wave of Hope
The DEEp OCEAN clinical study is assessing the safety of the investigational drug, bexicaserin, and its potential to reduce the number of seizures in children and adults with DEE.
Eligible participants include individuals aged 2 to 65 who have been diagnosed with Developmental and Epileptic Encephalopathies (DEE) and have experienced the onset of seizures from birth to 8 years of age for people with Lennox-Gastaut Syndrome (LGS) or birth to 5 years old for people with DEE (other). Additionally, they have experienced an average of four seizures per month over the past three months.
Study Sites in the United States:
- MultiCare Health System, Mary Bridge Pediatrics – Tacoma, WA
- NW FL Clinical Research Group, LLC – Gulf Breeze, FL
- Rare Disease Research, LLC – Atlanta, GA
- Mid-Atlantic Epilepsy and Sleep Center – Bethesda, MD
- Research Institute of Orlando LLC – Orlando, FL
- Institute of Neurology and Neurosurgery at Saint Barnabas, LLC – Livingston, NJ
Additional Information:
Visit the DEEp OCEAN Study Website
The information here is not intended to provide diagnosis, treatment, or medical advice and should not be considered a substitute for advice from a healthcare professional. The content provided is for informational purposes only. LGS Foundation is not responsible for actions taken based on the information included on this webpage. Please consult with a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options.
Updated 01/15/25 (KK)